Caliway Biopharmaceuticals Joins Prestigious FTSE Taiwan Indices

Company Strengthens Position in Biotech Sector with New Inclusion

NEW TAIPEI CITY, Dec. 6, 2024 /PRNewswire/ — Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) has been included in the FTSE TWSE Taiwan Mid-Cap 100 Index and the FTSE TWSE Taiwan Eight Industries Index. This inclusion, effective December 23, 2024, marks a significant achievement, underscoring the company’s growing presence in the pharmaceutical and healthcare industries.

The FTSE TWSE Taiwan Mid-Cap 100 Index was established in 2004 to track Taiwan’s top 100 mid-cap companies by market capitalization, excluding the leading 50 companies in the FTSE TWSE Taiwan 50 Index. This index is particularly focused on growth sectors, making it an ideal platform for Caliway, which is positioned for further growth.

In addition, the FTSE TWSE Taiwan Eight Industries Index was launched in 2007 to reflect the performance of eight major industry sectors in Taiwan. Being included in this index showcases Caliway’s leadership in the biopharmaceutical sector, reinforcing its status among the top companies in its industry.

This inclusion is a testament to Caliway’s strong market performance and growth potential, enhancing its visibility among both local and international investors. With a commitment to innovation in biopharmaceuticals, Caliway aims to provide cutting-edge therapeutic solutions while adding value for its stakeholders.

The company plans to leverage its innovative product pipeline and competitive market positioning to further impact the biopharmaceutical landscape in Taiwan and abroad.

About FTSE TWSE Taiwan Index Series

The FTSE TWSE Taiwan Index Series is a collaboration between the Taiwan Stock Exchange Corporation (TWSE) and FTSE Russell. This series offers various tools for market participants to engage with the Taiwanese market, including indices for trading derivatives and index-tracking funds.

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals Co., Ltd. (TWSE-6919) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics. The company strives to enhance patient outcomes through advanced solutions.

Disclaimer

This article includes forward-looking statements, which are based on various assumptions and are subject to risks and uncertainties. Actual results may differ significantly from those predicted. The company is under no obligation to update this information unless required by law.

For more information, please visit:

www.caliway.com.tw

https://taiwanindex.com.tw/news/337

View original content to download multimedia: here

SOURCE Caliway Biopharmaceuticals